GSK Plc ADR (GSK) concluded trading on Wednesday at a closing price of $38.03, with 13.45 million shares of worth about $511.62 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 12.58% during that period and on July 23, 2025 the price saw a gain of about 2.73%. Currently the company’s common shares owned by public are about 2.04B shares, out of which, 2.02B shares are available for trading.
Stock saw a price change of -0.65% in past 5 days and over the past one month there was a price change of -0.60%. Year-to-date (YTD), GSK shares are showing a performance of -3.35% which increased to 12.45% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $31.72 but also hit the highest price of $44.67 during that period. The average intraday trading volume for GSK Plc ADR shares is 5.32 million. The stock is currently trading -0.11% below its 20-day simple moving average (SMA20), while that difference is down -2.24% for SMA50 and it goes to 2.82% higher than SMA200.
GSK Plc ADR (NYSE: GSK) currently have 2.04B outstanding shares and institutions hold larger chunk of about 18.20% of that.
The stock has a current market capitalization of $76.83B and its 3Y-monthly beta is at 0.51. PE ratio of stock for trailing 12 months is 19.74, while it has posted earnings per share of $1.93 in the same period. Its PEG reads 1.97 and has Quick Ratio of 0.58 while making debt-to-equity ratio of 1.30. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GSK, volatility over the week remained 3.53% while standing at 2.07% over the month.
Stock’s fiscal year EPS is expected to rise by 10.34% while it is estimated to increase by 12.31% in next year. EPS is likely to grow at an annualized rate of 10.02% for next 5-years, compared to annual growth of -11.63% made by the stock over the past 5-years.
Coverage by Exane BNP Paribas stated GSK Plc ADR (GSK) stock as a Neutral in their note to investors on April 15, 2025, suggesting a price target of $35.25 for the stock. Stock get a Hold rating from Jefferies on November 12, 2024.
